{"symbol":"PFE","fiscalQuarter":"Q2-2026","reportDate":"2026-07-29","reportTime":"BMO","status":"upcoming","company":{"name":"Pfizer Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/PFE/earnings/Q2-2026","preBrief":{"companySnapshot":"Pfizer Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines, particularly in the health care sector. With a market cap of $140 billion, Pfizer plays a crucial role in addressing global health challenges, including the ongoing demand for vaccines and treatments.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS indicates the company's profitability and is a key measure for investors to assess financial health.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.","consensus":"N/A"},{"name":"Vaccine Sales","why":"As a major player in vaccine production, sales figures will provide insight into market demand and future revenue streams.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock saw a modest increase of 0.57% the following day, reflecting positive market sentiment.","promises":[]},"wallStreetExpectations":{"summary":"Overall expectations for Pfizer's upcoming earnings are cautious, with investors keenly watching for any signs of revenue growth and profitability amidst a competitive pharmaceutical landscape.","bullCase":"If Pfizer can demonstrate strong vaccine sales and continued profitability, it may signal robust demand and market confidence, potentially driving the stock higher.","bearCase":"Conversely, if the earnings report reveals weaker-than-expected sales or profit margins, it could raise concerns about the company's growth trajectory and lead to a decline in stock price."},"optionsSignal":{"impliedMove":"9.1%","context":"The options market is pricing in a significant move of approximately 9.1%, suggesting that traders anticipate volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+5.63%","reaction":"+0.57%"},{"quarter":"Q4-2025","epsSurprise":"+16.81%","reaction":"-3.34%"},{"quarter":"Q3-2025","epsSurprise":"+32.22%","reaction":"-1.46%"},{"quarter":"Q2-2025","epsSurprise":"+36.36%","reaction":"+5.18%"},{"quarter":"Q1-2025","epsSurprise":"+43.75%","reaction":"+3.21%"}],"pivotalQuestions":[{"question":"What are the specific sales figures for Pfizer's vaccine products this quarter?","whyItMatters":"Given the ongoing demand for vaccines, these figures will be critical in assessing Pfizer's market position and future revenue potential."},{"question":"How does management view the competitive landscape for upcoming products?","whyItMatters":"Understanding management's perspective on competition will help investors gauge potential challenges and opportunities in the market."}],"thesisBreakLevels":{"bullTrigger":"A vaccine sales increase of 15% or more year-over-year would confirm the bull case.","bearTrigger":"A decline in vaccine sales or lower-than-expected EPS would confirm the bear case.","context":"The core debate this quarter revolves around Pfizer's ability to sustain growth in a competitive environment, particularly in vaccine sales."},"scenarioPlaybook":{"beatAndRaise":"If Pfizer beats expectations and raises guidance, history suggests the stock could rise by an average of 0.46% the next day.","inLineCautious":"If results are in line but management provides cautious commentary, the stock may see muted movement as investors reassess growth prospects.","miss":"Should Pfizer miss expectations, the stock could decline, with historical patterns suggesting an average drop of around 0.46%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate the strength of Pfizer's vaccine sales, which could exceed expectations due to ongoing global health concerns.","supportingPoints":["Pfizer's historical EPS beat rate is 100%, indicating strong operational performance.","Options pricing suggests a larger move than historical averages, indicating potential for significant surprises.","Recent trends in global health indicate sustained demand for vaccines, which may not be fully reflected in current estimates."],"riskToConsensus":"If vaccine sales come in significantly above expectations, it could challenge current market assumptions."},"whatToListenFor":["Details on vaccine sales performance and any new contracts.","Management's outlook on competition and market share.","Updates on pipeline products and their expected launch timelines.","Any commentary on cost management and profit margins.","Insights into global health trends affecting demand."],"metaDescription":"Pfizer (PFE) reports Q2 2026 earnings July 29. Investors are watching for vaccine sales performance and EPS figures."}}